Nyrada, Inc. · ASX:NYR
Nyrada — Bell Potter Healthcare Conference 2026
13 slides from Nyrada's conference presentation, Nov 19, 2026
Slide 1: Bell Potter Healthcare Conference 2026
Bell Potter Healthcare Conference 2026 Building the Future of TRPC-targeted Therapies 19 November 2026 ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be considered as an offer or invitation to subscribe for, or purchase any securities in NYR, or as an inducement to purchase any securities in NYR. No agreement to subscribe for secu
Slide 3: Investment Highlights
Investment Highlights Advancing first-in-class TRPC inhibitor with multiple near-term value catalysts Platform asset with Positive Phase I safety Near term Phase IIa High unmet need Strong IP & Uniquely Multiple near-term data supporting and pharmacokinetic safety and efficacy opportunity in Experie
Slide 4: Xolatryp Mechanism of Action
Xolatryp® Mechanism of Action Nyrada’s lead candidate Xolatryp® is a clinically validated target and gatekeeper of calcium influx with broad therapeutic potential Overview Cardioprotection • Xolatryp® is a third generation TRPC 3/6/7 channel inhibitor TRPC3 TRPC6 TRPC7 • Highly differentiated and cl
Slide 5: TRPC Channels: Clinical Landscape & Validation
TRPC Channels: Clinical Landscape & Validation Growing industry investment supports the emergence of TRPC therapeutics • Genetic validation and strong preclinical data have led to advancing clinical programs First TRPC Program to Reach Phase III across cardiovascular, kidney, neurological and fibrot
Slide 6: Xolatryp in Cardiac Reperfusion Injury
Xolatryp® in Cardiac Reperfusion Injury Well defined and uncontested $US3bn US market opportunity
Slide 7: Heart Attack (STEMI)
Heart Attack (STEMI) STEMI results in a hyper-activation of TRPC channels Overview STEMI • Atherosclerotic plaque restricts blood flow to a region of the heart muscle resulting in Myocardial Infarction (MI) “Heart attack” • STEMI (ST-elevation myocardial infarction) is a blockage • Myocardium oxygen
Slide 8: Current Standard Treatment for STEMI Heart Attack
Current Standard Treatment for STEMI Heart Attack Up to ~50% of heart injury may be caused by reperfusion, representing a major remaining therapeutic challenge Infarct size as a driver of heart failure Current Standard of Care for The Clinical Paradox from PCI risk and mortality STEMI patients Revie
Slide 9: PROTECT-MI: Phase IIa Trial
PROTECT-MI: Phase IIa Trial Phase IIa Cardiac Reperfusion Injury trial recruiting – 5 sites active, 5 patients dosed PROTECT-MI is a Phase IIa randomised, double-blind, placebo-controlled study 100 evaluable patients (drug:placebo randomisation evaluating Xolatryp® in STEMI patients undergoing PCI S
Slide 10: STEMI Heart Attack – Large Uncontested Market Opportunity
STEMI Heart Attack – Large Uncontested Market Opportunity US$3bn STEMI opportunity US Market Opportunity ~750K >80% ~600K US$5,000 US$3bn = STEMI¹ STEMI related PCI¹ Illustrative price² ✕ ✕ Total addressable Estimated PCI market in the US Annual STEMI Illustrative price procedures related incidence
Slide 11: Catalysts
Catalysts Multiple near-term milestones over the next 18 months 2H CY26 1H CY27 2H CY27 • PROTECT-MI Phase IIa execution: ongoing patient • PROTECT-MI Phase IIa execution: ongoing patient • Phase IIa PROTECT-MI topline data readout recruitment and site activations across Australian recruitment and s
Slide 12: Diversified Pipeline
Diversified Pipeline Multiple compelling TRPC opportunities in indications of high unmet need Target Strategy and Upcoming Applications Pre-clinical Phase I Phase II Phase III Indication Catalysts • Safety review in H2 CY26 Cardiac Phase IIa • Topline data in Q3/Q4 CY27, Cardioprotection Reperfusion
Slide 13: Key Links
Key Links • Cardioprotection • Oncology • PROTECT-MI website - https://www.protect-mi.com • Preclinical cardiomyopathy study - • PROTECT-MI NIH Entry - https://bit.ly/4cB2fF9 https://bit.ly/4yR9BgD • FDA IND Feedback - https://bit.ly/4zyu9dZ • Preclinical cardiomyopathy pilot study - https://bit.ly/